[Retracted] Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma

Table 2

Comparison of short-term treatment effects between the observation group and the control group.

Curative effect	1 month			3 months
	Observation group	Control group		Observation group	Control group
CR	18 (58.1%)	19 (61.3%)		15 (48.4%)	10 (32.3%)
PR	10 (32.3%)	7 (22.6%)		9 (29.0%)	6 (19.4%)
SD	3 (9.7%)	3 (9.7%)		5 (16.1%)	7 (22.6%)
PD	0	2 (6.5%)		2 (6.5%)	7 (22.6%)
ORR	28 (90.3%)	26 (83.9%)	0.354	24 (77.4%)	16 (51.6%)	0.031
DCR	31 (100%)	29 (93.5%)	0.246	29 (93.5%)	23 (74.2%)	0.040

CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; ORR: objective response rate; DCR: disease control rate.